Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -Susuqehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna
September 12, 2017 2:33 PM EDTSusquehanna options strategist Alison Edwards notes speculative bullish options flow in AbbVie (NYSE: ABBV), with management presenting at a healthcare conference, as an investor sold 2k Nov 85/92.5 call spreads at $4.78 (getting long the 92.5 strike options), possibly a buyer of 2,500 Jan 95 Calls for $1.50, while... More
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
September 11, 2017 8:03 AM EDTAbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).1 Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20* and low disease activity (LDA)**.1 All ranked secondary endpoints were also achieved with both doses.1 Upadacitinib is not... More
Abbvie (ABBV): IPR Victory Translates Into A 36% PT Increase - Cowen
September 11, 2017 6:16 AM EDTCowen analyst, Steve Scala, reiterated his Outperform rating on shares of Abbvie (NYSE: ABBV) and raised his price target to $95 from $70 noting that last week's IPR victory targeting a Humira formulation patent is important leading the analyst to give ABBV the... More
